Pacific Biosciences of California, Inc. (FRA:P09)
1.400
-0.007 (-0.48%)
Last updated: Feb 20, 2026, 9:59 AM CET
FRA:P09 Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 279.51 | 55.37 | 179.91 | 325.09 | 460.73 |
Short-Term Investments | - | 334.56 | 451.51 | 447.23 | 583.68 |
Cash & Short-Term Investments | 279.51 | 389.93 | 631.42 | 772.32 | 1,044 |
Cash Growth | -28.32% | -38.25% | -18.24% | -26.05% | 227.59% |
Accounts Receivable | 35.45 | 27.52 | 36.62 | 18.79 | 24.24 |
Receivables | 35.45 | 27.52 | 36.62 | 18.79 | 24.24 |
Inventory | 49.29 | 58.76 | 56.68 | 50.38 | 24.6 |
Prepaid Expenses | 10.79 | 14.78 | 17.04 | 10.29 | 7.39 |
Restricted Cash | 1.55 | 0.69 | 0.3 | 0.3 | 0.5 |
Other Current Assets | - | 4 | - | - | - |
Total Current Assets | 376.58 | 495.68 | 742.05 | 852.07 | 1,101 |
Property, Plant & Equipment | 65.84 | 46.6 | 69.03 | 81.34 | 79.12 |
Goodwill | 317.76 | 317.76 | 462.26 | 409.97 | 409.97 |
Other Intangible Assets | 15.12 | 389.57 | 456.98 | 410.25 | 410.98 |
Other Long-Term Assets | 8.77 | 10.84 | 15.7 | 13.45 | 5.76 |
Total Assets | 784.08 | 1,260 | 1,746 | 1,767 | 2,007 |
Accounts Payable | 20.77 | 16.59 | 15.06 | 12.03 | 11 |
Accrued Expenses | 33.65 | 21.51 | 44.74 | 34.58 | 39.27 |
Current Portion of Long-Term Debt | - | - | 0.49 | 1.84 | 1.61 |
Current Portion of Leases | - | 10.03 | 9.59 | 8.89 | 7.71 |
Current Unearned Revenue | - | 13.86 | 16.34 | 30.5 | 10.98 |
Other Current Liabilities | - | 4.31 | 8.8 | 175.5 | 1.15 |
Total Current Liabilities | 54.42 | 66.3 | 95.03 | 263.34 | 71.71 |
Long-Term Debt | 645.38 | 647.49 | 892.24 | 896.68 | 896.07 |
Long-Term Leases | 57.04 | 14.91 | 31.61 | 41.07 | 49.97 |
Long-Term Unearned Revenue | 19.87 | 5.9 | 5.53 | 1.79 | 25.05 |
Other Long-Term Liabilities | 2.03 | 19.25 | 20.3 | 1.3 | 173.19 |
Total Liabilities | 778.73 | 753.85 | 1,045 | 1,204 | 1,216 |
Common Stock | 5.35 | 0.29 | 0.27 | 0.23 | 0.22 |
Additional Paid-In Capital | - | 2,655 | 2,540 | 2,100 | 2,010 |
Retained Earnings | - | -2,149 | -1,839 | -1,532 | -1,218 |
Comprehensive Income & Other | - | 0.42 | 0.22 | -4.77 | -1.09 |
Shareholders' Equity | 5.35 | 506.59 | 701.3 | 562.9 | 790.99 |
Total Liabilities & Equity | 784.08 | 1,260 | 1,746 | 1,767 | 2,007 |
Total Debt | 702.42 | 672.43 | 933.93 | 948.48 | 955.36 |
Net Cash (Debt) | -422.92 | -282.5 | -302.51 | -176.16 | 89.05 |
Net Cash Growth | - | - | - | - | -67.83% |
Net Cash Per Share | -1.41 | -1.03 | -1.19 | -0.78 | 0.44 |
Filing Date Shares Outstanding | 301.91 | 297.85 | 267.95 | 247.08 | 221.18 |
Total Common Shares Outstanding | 301.91 | 294.42 | 267.74 | 226.51 | 220.98 |
Working Capital | 322.17 | 429.38 | 647.02 | 588.74 | 1,029 |
Book Value Per Share | 0.02 | 1.72 | 2.62 | 2.49 | 3.58 |
Tangible Book Value | -327.54 | -200.74 | -217.94 | -257.32 | -29.97 |
Tangible Book Value Per Share | -1.08 | -0.68 | -0.81 | -1.14 | -0.14 |
Machinery | - | 69.13 | 68.03 | 60.86 | 49.8 |
Construction In Progress | - | 2.28 | 1.34 | 4.7 | 2.3 |
Leasehold Improvements | - | 33.77 | 35.23 | 34.13 | 31.11 |
Order Backlog | - | 31.2 | 18.7 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.